Novocure LtdChange company Symbol lookupSelect an option...NVCR Novocure LtdCHEA Chenghe Acquisition CoCRIS Curis IncPIXY ShiftPixy IncRVLP RVL Pharmaceuticals PLCNAUT Nautilus Biotechnology IncBOF BranchOut Food IncSPRC Scisparc LtdNRSN Neurosense Therapeutics LtdACNT Ascent Industries CoGo
Based in Jersey
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company’s key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
Company Profile
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company’s key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
Valuation Ratios
- Price/Earnings (TTM)
- --
- Price/Sales (TTM)
- 3.49x
- Price/Book (MRQ)
- 4.26x
- Price/Cash Flow (TTM)
- --
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in thousands.
Company Officers
- William F. DoyleChmn.
- Asaf DanzigerPres.
- Ashley CordovaCFO
- Frank X. LeonardCorp.Exec.
- Wilhelmus C. M. GroenhuysenCOO
Address
- No. 4 The Forum, Grenville Street
- Saint Helier, JE2 4UF
- Jersey
- Phone: 1534756700
- https://www.novocure.com/
Insider Trading
During the most recent quarter, 3K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.